Jefferies Adjusts Bayer Price Target Following Q3 Results
Investment firm Jefferies has raised its price target for Bayer AG shares from 46 to 48.50 euros while maintaining a 'Hold' rating.
Stocks · News reference
Bayer to Present New Cardiovascular, Kidney, and Stroke Data at 2026 AHA Scientific Sessions
Bayer announced it will showcase new clinical data from its cardiovascular, kidney, and stroke portfolios at the upcoming American Heart Association Scientific Sessions.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bayer CEO Bill Anderson Speaks at Global Peter Drucker Forum 2026
Bayer CEO Bill Anderson participated as a featured speaker at the 18th Global Peter Drucker Forum in Vienna.
DZ BANK Issues Buy Rating for Bayer AG
DZ BANK has initiated coverage or updated its outlook on Bayer AG, assigning the stock a 'Buy' rating.
Bayer Updates Financial Outlook and Debt Reduction Targets
Bayer AG has raised its cash flow forecast and provided an updated target for debt reduction by the end of the year, supported by a significant transaction with Apollo.
Bayer Launches New Biologicals Brand in Latin America
Bayer has launched a new brand for biological products in Latin America, with the first product, Curvet, developed in partnership with Sound Agriculture.
Bayer Receives First-Line Approval for Sevabertinib in China
Bayer's lung cancer medication Sevabertinib has been approved by China's National Medical Products Administration for use as a first-line therapy for patients with advanced HER2-mutated non-small cell lung cancer.